Podcasts

Articles

Videos

Results of a single-center study presented at the 2022 ASCO Annual Meeting showed that oral minoxidil may be effective in treating late alopecia. Moving forward, these efforts in survivorship care will need to be expanded to less resourced areas, experts said.  

Oral Minoxidil Demonstrates Efficacy in Treating Later Stage Alopecia in Cancer Survivors

At the 2022 Supportive Care in Cancer Annual Meeting, Jeffrey Crawford, MD, highlighted the potential value of biosimilars in reducing gaps in care for the treatment of febrile neutropenia. 

Biosimilars May Reduce Disparities in Febrile Neutropenia Treatment

Data from the phase 1/2 EPCORE NHL-2 trial suggest that the combination of epcoritamab and R-CHOP is both effective and manageable in treating patients with high-risk diffuse large B-cell lymphoma.

Frontline Epcoritamab/R-CHOP Combination Induces 100% ORR in Patients With High-Risk DLBCL

Utilization of specialty nurse practitioner driven teams and use of individualized pain protocols for patients admitted with vaso-occlusive pain crisis improves quality of life for patients with sickle cell disease, and decreased hospital stay times.

Implementation of Individualized Pain Management in Vaso-occlusive Pain Crisis 

The FDA has approved lisocabtagene maraleucel as a second-line treatment for patients with relapsed or refractory large B-cell lymphoma. 

FDA Approves Liso-Cel for Second-Line Large B-Cell Lymphoma 

Updated data from the phase 3 BELIEVE trial revealed a sustained reduction in the need for red blood cell transfusions among patients with β-thalassemia who received treatment with luspatercept-aamt.

Luspatercept Linked With Maintained Reduction in Transfusion Dependence Among Patients With β-Thalassemia

This year’s congress showcased strategies for communicating sensitive topics, patient experiences with immunotherapy treatments, updates in the utility of
medical cannabis, and more. 

ONS Annual Congress Focuses on Increasing Nurse Comfort and Patient Understanding in Cancer Care

Laura J. Zitella, MS, RN, ACNP-BC, AOCN, recounts key nursing considerations with targeted therapy for chronic lymphocytic leukemia, and third-line diffuse large b-cell lymphoma options.  

Zitella Weighs In On Overarching Treatment Strategies in Hematologic Malignancies

The FDA approval of dabrafenib plus trametinib for BRAF V600E–mutated unresectable or metastatic solid tumors highlights a potential need for routine BRAF testing in clinical practice, experts say.  

FDA Grants Accelerated Approval to Dabrafenib Plus Trametinib for BRAF V600E–Mutated Solid Tumors

Heavily pretreated pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia maintained response with tisagenlecelucel according to long-term follow-up data from the phase 2 ELIANA trial. 

All News